Generics Bulletin Explains: US Adalimumab Outlook Brightens At Mid-Point Of 2024

As PBMs Face Increasing Pressure Over Suppressing Uptake For Humira Biosimilars

 
• By David Wallace
  
Chart showing trending up in 2024
Uptake is beginning to ramp up for US adalimumab biosimilars in 2024 • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products